骨质疏松是一种以骨量减少和骨微结构破环为特征而导致骨折危险性增加的疾病。Salubrinal是真核翻译起始因子2α(e IF2α)的选择性抑制剂,保护细胞免于内质网应激。前期工作表明salubrinal可促进骨损伤愈合,但是对骨丢失的作用尚需探索。本实验使用骨量减少的动物模型--鼠尾悬吊小鼠,验证以下假设:salubrinal通过抑制小鼠破骨细胞发育和骨细胞凋亡治疗骨质疏松。C57BL/6雌性小鼠(14周龄)随机分为3组:年龄对照组、鼠尾悬吊对照组和治疗组(n=20)。悬吊治疗组每天皮下注射salubrinal(1mg/kg),持续2周,鼠尾悬吊对照组小鼠注射同等体积的溶剂。实验前后分别进行骨密度测量。给药2周后处死小 Osteoporosis is a disease characterized by reduced bone mass and disruption of the microstructure of the bone resulting in an increased risk of fracture. Salubrinal is a selective inhibitor of the eukaryotic translation initiation factor 2α (e IF2α), which protects cells from endoplasmic reticulum stress. Previous work showed that salubrinal can promote bone injury healing, but the role of bone loss still needs to be explored. This experiment used an animal model of bone loss - mouse tail suspension mice to verify the hypothesis that salubrinal treats osteoporosis by inhibiting mouse osteoclast development and osteoblast apoptosis. C57BL / 6 female mice (14 weeks old) were randomly divided into 3 groups: age control group, tail suspension control group and treatment group (n = 20). The suspension treatment group was subcutaneously injected with salubrinal (1 mg / kg) subcutaneously daily for 2 weeks, and mice in the tail suspension control group were injected with the same volume of solvent. Before and after the experiment were measured bone mineral density. Two weeks after the administration, the mice were sacrificed